Cargando…

Ablation of reactive astrocytes exacerbates disease pathology in a model of Alzheimer's disease

The role of astrocytes in the progression of Alzheimer's disease (AD) remains poorly understood. We assessed the consequences of ablating astrocytic proliferation in 9 months old double transgenic APP23/GFAP‐TK mice. Treatment of these mice with the antiviral agent ganciclovir conditionally abl...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsouri, Loukia, Birch, Amy M., Renziehausen, Alexander W. J., Zach, Carolin, Aman, Yahyah, Steeds, Hannah, Bonsu, Angela, Palmer, Emily O. C., Mirzaei, Nazanin, Ries, Miriam, Sastre, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383629/
https://www.ncbi.nlm.nih.gov/pubmed/31799735
http://dx.doi.org/10.1002/glia.23759
Descripción
Sumario:The role of astrocytes in the progression of Alzheimer's disease (AD) remains poorly understood. We assessed the consequences of ablating astrocytic proliferation in 9 months old double transgenic APP23/GFAP‐TK mice. Treatment of these mice with the antiviral agent ganciclovir conditionally ablates proliferating reactive astrocytes. The loss of proliferating astrocytes resulted in significantly increased levels of monomeric amyloid‐β (Aβ) in brain homogenates, associated with reduced enzymatic degradation and clearance mechanisms. In addition, our data revealed exacerbated memory deficits in mice lacking proliferating astrocytes concomitant with decreased levels of synaptic markers and higher expression of pro‐inflammatory cytokines. Our data suggest that loss of reactive astrocytes in AD aggravates amyloid pathology and memory loss, possibly via disruption of amyloid clearance and enhanced neuroinflammation.